ApoA-I mimetic peptides are an emerging class of therapeutic agents whose antioxidant/anti-inflammatory properties and reverse cholesterol transport (RCT) are used to treat atherosclerosis and inflammatory disorders [88]. The gene discussed is APOA1; the disease is atherosclerosis.